Imperial College London
Portrait Picture

ProfessorVictoriaCornelius

Faculty of Medicine, School of Public Health

Professor in Medical Statistics and Trials Methodology
 
 
 
//

Contact

 

+44 (0)20 7594 1218v.cornelius

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

111Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Li:2021:10.1371/journal.pmed.1003515,
author = {Li, C and Chen, K and Cornelius, V and Tomeny, E and Wang, Y and Yang, X and Yuan, X and Qin, R and Yu, D and Wu, Z and Wang, D and Chen, T},
doi = {10.1371/journal.pmed.1003515},
journal = {PLoS Medicine},
pages = {1--14},
title = {Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study},
url = {http://dx.doi.org/10.1371/journal.pmed.1003515},
volume = {18},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundThe Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardiovascular disease (CVD) risk with a systolic blood pressure (SBP) goal of <120 mm Hg compared with a SBP goal of <140 mm Hg. Our study aimed to assess the applicability of SPRINT to Chinese adults. Additionally, we sought to predict the medical and economic implications of this intensive SBP treatment among those meeting SPRINT eligibility.Methods and findingsWe used nationally representative baseline data from the China Health and Retirement Longitudinal Study (CHARLS) (2011–2012) to estimate the prevalence and number of Chinese adults aged 45 years and older who meet SPRINT criteria. A validated microsimulation model was employed to project costs, clinical outcomes, and quality-adjusted life-years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment strategies (SBP goal of <120 mm Hg [intensive treatment] and SBP goal of <140 mm Hg [standard treatment]). Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to 124.8) million people in China. Of these, 66.4%, representing 77.2 (95% CI 69.3 to 85.0) million, were not being treated for hypertension, and 22.9%, representing 26.6 (95% CI 22.4 to 30.7) million, had a SBP between 130 and 139 mm Hg, yet were not taking antihypertensive medication. We estimated that over 5 years, compared to standard treatment, intensive treatment would reduce heart failure incidence by 0.84 (95% CI 0.42 to 1.25) million cases, reduce CVD deaths by 2.03 (95% CI 1.44 to 2.63) million cases, and save 3.84 (95% CI 1.53 to 6.34) million life-years. Estimated reductions of 0.069 (95% CI −0.28, 0.42) million myocardial infarction cases and 0.36 (95% CI −0.10, 0.82) million stroke cases were not statistically significant. Furthermore, over a lifetime, moving from standard to intensive treatment increased the mean QALYs from 9.51 to 9.87 (an increment of 0.38 [95% CI 0.13
AU  - Li,C
AU  - Chen,K
AU  - Cornelius,V
AU  - Tomeny,E
AU  - Wang,Y
AU  - Yang,X
AU  - Yuan,X
AU  - Qin,R
AU  - Yu,D
AU  - Wu,Z
AU  - Wang,D
AU  - Chen,T
DO  - 10.1371/journal.pmed.1003515
EP  - 14
PY  - 2021///
SN  - 1549-1277
SP  - 1
TI  - Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study
T2  - PLoS Medicine
UR  - http://dx.doi.org/10.1371/journal.pmed.1003515
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000626602400003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003515
UR  - http://hdl.handle.net/10044/1/89155
VL  - 18
ER  -
Download